Isabelle Rivière received her Ph.D. in Cellular and Molecular Biology from the University ofParis, France. She conducted her graduate studies at the Institut Curie (Paris) and at the Whitehead Institute (Cambridge, MA). After completing her postdoctoral work at NYU, she joined the faculty of Memorial Sloan-Kettering Cancer Center where she developed novel strategies for cell therapies and immunotherapies. Over the past 20 years, her laboratory has conceived and implemented cell manufacturing processes to support multiple CAR T cell-based clinical trials for the treatment of hematological malignancies and solid tumors. She recently joined Takeda Development Center Americas, Inc as VP, Cell Therapy Technologies and ProductEngine. She currently serves on the Board of Directors of the American Society of Gene and CellTherapy (ASGCT). She has served as a member on the Board of Directors of the Alliance for Regenerative Medicine (ARM) and on the Advisory Board of the National Science Foundation (NSF) Engineering Research Center (ERC) for Cell Manufacturing Technologies (CMaT). She is Scientific Co-founder of Juno Therapeutics Inc. and of Mnemo Therapeutics and received the Jerry Mendell Award for Translational Science in 2023

Talks

• Evolving CAR Cell Therapy Engineering: Challenges & Opportunities
• Evolving CAR Cell Therapy Engineering: Challenges & Opportunities